Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 569 results for "ranbaxy lab"

Ranbaxy Lab slips as net loss widens in Q3

Ranbaxy Laboratories fell 0.82% to Rs 701.10 at 15:20 IST on BSE after the company reported consolidated net loss of Rs 1029.72 crore in Q3 December 2014, higher than net loss of Rs 158.94 crore in Q3 December 2013. The Q3 result was announced ... Capital Market, 3 days ago

1 images for "ranbaxy lab"

Business Today India, 3 days ago

Ranbaxy Lab gains even as US court rejects co's appeal to block ANDA nod for 2 drugs

Ranbaxy Laboratories is currently trading at Rs. 620.00, up by 4.55 points or 0.74% from its previous closing of Rs. 615.45 on the BSE. The scrip opened at Rs. 611.10 and has touched a high and low of Rs. 621.75 and Rs. 611.10 respectively. So far ...
 Arihant Capital2 months ago Ranbaxy Laboratories : Labs to take its novel drug Synriam to Africa  4 Traders1 month ago Approval for Ranbaxy to launch Synriam in 7 African nations  Moneycontrol.com1 month ago Ranbaxy gets nod to launch Synriam in 7 African countries  Moneycontrol.com1 month ago
Business Today India

Ranbaxy Lab in the pink of health

Ranbaxy Laboratories rose 3.69% to Rs 635 at 12:21 IST on BSE after the company said it has launched Infimab, the first Remicade (Infliximab) biosimilar in India. The announcement was made during market hours today, 1 December 2014. ...
 Capital Market2 months ago Fortis HealthWorld Acquires Pharma Retail Chain CRS Health  VC Circle1 month ago Ranbaxy Labs launches arthritis drug Infimab in India  Business Today India2 months ago Ranbaxy launches Indias first biosimilar of Infliximab drug, Infimab  Moneycontrol.com2 months ago

India,United States : CCI grants approval for SUN PHARMA and RANBAXY LABS merger [TendersInfo (India)]

The Competition Commission of India (CCI) has granted approval for the proposed merger between the Sun Pharma and Ranbaxy Labs. The merger will result in a combined entity with annual sales worth $4.3 billion, making it the fifth-largest generic ...
 Pharmacy Choice1 month ago Sun Pharma gains after CCI approves merger with Ranbaxy Lab  Business Standard1 month ago Sun Pharma and Ranbaxy Lab will be in focus after CCI approves merger  Capital Market1 month ago CCI clears Sun Pharma's deal to buy Ranbaxy Labs  The Gulf Today1 month ago

Ranbaxy Lab, Sun Pharma gain as CCI clears deal

Mumbai, Dec 9 (PTI) Shares of Ranbaxy Lab and Sun Pharma today gained as much as 4 per cent after the drug-makers got fair trade watchdog CCI's approval for their long-pending USD 4-billion merger, though with riders. Ranbaxy Lab's stock rose 4 per ...
 Press Trust of India1 month ago Ranbaxy Lab, Sun Pharma gain up to 3.5 per cent as CCI clears deal  Economic Times1 month ago Ranbaxy, Sun Pharma gain up to 3.5% as CCI clears deal  Economic Times1 month ago Ranbaxy, Sun Pharma gain as CCI clears deal  Rediff.com1 month ago
Reuters India

Ranbaxy Lab sues US FDA for revoking drug approvals

Last month, FDA told Ranbaxy that it believed its decisions to grant the company tentative approvals for copies of Nexium and Roche AG's antiviral Valcyte were "in error". Ranbaxy Laboratories Ltd has sued thUS Food and Drug Administration (FDA) for revoking ...
 India Infoline2 months ago Ranbaxy Labs sues FDA  Reuters India2 months ago Ranbaxy sues FDA for revoking approvals for Nexium, Valcyte  Moneycontrol.com2 months ago Ranbaxy sues FDA for revoking nods to 2 generic drugs  The Financial Chronicle2 months ago

Divis Labs, Glenmark, Ranbaxy to get astro support: Gupta

According to Satish Gupta of astrostocktips, pharma stocks like Divis Labs, Glenmark Pharma, Ipca Lab and Ranbaxy Labs will get astro support.
 Money Control1 month ago

Ranbaxy Lab drops after reports of suing USFDA for revoking drug approvals

Ranbaxy Laboratories declined 2.03% to Rs 629.10 at 15:25 IST on BSE on reports company has sued the US Food and Drug Administration for revoking approvals granted to the firm to launch copies of two drugs. Meanwhile, the S&P BSE Sensex was down 24.44 points ...
 Business Standard2 months ago

Buy Ranbaxy Labs; target of Rs 800: Motilal Oswal

Brokerage house Motilal Oswal is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target price of Rs 800, in its research report dated January 28, 2015.
 Money Control1 day ago Accumulate Ranbaxy Labs; target of Rs 670: KRChoksey  Money Control2 months ago
Money Control

Stocks in news: Bharti, Idea, Titan, LT, Ranbaxy, Hindalco

Bharti Airtel | Tata Motors | Idea Cellular | Yes Bank | GMR Infrastructure | Amara Raja Batteries | Titan Company | Sadbhav Engineering | Gammon Infrastructure | Larsen and Toubro | Ranbaxy Labs | Hindalco Industries | GE Shipping | Cholamandalam Investment ...
 Money Control3 days ago Stocks in news: TVS Motor, SBI, Ranbaxy, Hindalco, Maruti  Money Control4 days ago Stocks in news: Ranbaxy, Maruti, JP Associates, IOC, KEC  Money Control1 month ago Stocks in news: Infosys, Ranbaxy, LT, Bharti, Fin Tech  Money Control2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less